
Nearly four years of follow-up showed a larger reported overall-survival benefit, while exploratory analyses found disease-free survival gains across baseline MRD groups.
Regeneron reported longer-term results from its Phase 3 C-POST trial, finding a 37% reduction in the risk of death with adjuvant Libtayo versus placebo after a median 44 months of follow-up. Overall survival was a secondary endpoint; the hazard ratio was 0.63, with a 95% confidence interval of 0.36 to 1.11.
The trial studied patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation. Among placebo patients whose cancer recurred, 61 of 69, or 88%, later received Libtayo, according to Regeneron.
An exploratory analysis found improved disease-free survival with Libtayo among patients who were minimal residual disease-negative at baseline (HR 0.45) and those who were MRD-positive (HR 0.24). The data were presented at the 2026 European Society for Medical Oncology meeting.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.